Growth in 340B covered entities’ use of contract pharmacies to dispense 340B drugs, coupled with growth in pharmacy benefit managers’ control over these pharmacies, has given PBMs an outsized, profit-driven role in the 340B program that does not benefit patients, drug makers and independent oncology practices recently argued to the Federal Trade Commission.
Pharmaceutical Research and Manufacturers of America (PhRMA) and Community Oncology Alliance (COA) submitted comments to the FTC in response to the commission’s late February call for public input on PBMs’ business practices and their effect on drug affordability and access. Groups that represent 340B covered entities submitted comments too. FTC launched a formal investigation into PBM practices on June 7.
Drug makers and independent oncology practices slammed pharmacy benefit managers’ role in 340B contract pharmacy growth in recent public comment to the Federal Trade Commission.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
